Compare Endeavour Silver Corp (EXK) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Mesoblast Limited — how do they compare? Endeavour Silver Corp trades at $8.84 (market cap $2.46B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Endeavour Silver Corp is the larger of the two by market cap, and Endeavour Silver Corp is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and Mesoblast Limited for 14 Days on average.
| EXK | MESO | |
|---|---|---|
Market Cap | $2.46B | $1.81B |
Volume | 5,827,665 | 240,620 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $20.96 |
52-Week Low | $7.07 | $13.19 |
Typical Hold Time | 25 Days | 14 Days |
Enterprise Value | $2.47B | $1.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.32, down 4.04% on the day, amid a bearish technical signal. The company reported a net loss of $119.1M in 2025 but expects a significant turnaround in 2026 with projected net income of $66M. Recent news highlights operational progress at the Terronera and Kolpa mines, though temporary disruptions have occurred. Analyst consensus is strongly bullish with a $10.50 price target, but technical indicators show selling pressure.
The outlook is mixed: strong analyst support and projected profitability in 2026 present upside, but near-term technical weakness and operational risks like mine blockades pose challenges. The stock's valuation multiples are elevated relative to current earnings, requiring successful execution of growth plans to justify further gains.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
